SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice

ARS Pharmaceuticals faces a securities class action alleging it inadequately disclosed the risk that CVS Caremark's planned July 1, 2026 formulary decision for neffy could be deferred until January 2027. After ARS disclosed on June 24 that no new coverage decision had been issued, SPRY fell $2.52, or 23.9%, from $10.54 to $8.02 the following session. The missed cycle delayed potential expanded access during the summer and back-to-school periods; while overall commercial coverage was about 93% at year-end 2025, only roughly 57% of covered lives had access without prior authorization.

Analysis

The actionable issue is not litigation itself—early plaintiff-firm announcements rarely alter enterprise value—but the implied reset in neffy’s near-term conversion curve. The missed formulary window removes the highest-seasonality demand period and likely shifts a meaningful portion of incremental prescriptions into 2027, while prior-authorization friction raises abandonment risk and weakens operating leverage. For a commercial-stage biotech, this can force consensus revenue and cash-burn revisions before the next earnings cycle, making the equity vulnerable to further multiple compression even after the initial gap down.

CVS is not a direct beneficiary or liability bearer: its formulary process is unlikely to be financially material to enterprise earnings. The relevant competitive read-through is that prescribing behavior will favor incumbent epinephrine auto-injector access where plan workflows are established; the commercial disadvantage for SPRY is distribution execution rather than product efficacy. Watch weekly prescription/dispense data, gross-to-net commentary, and cash runway—if prescription growth remains resilient despite access friction, the market has likely over-discounted the delay.

Over the next 1-3 months, the principal catalyst is management’s revised 2026 revenue, payer-access, and cash-use framework, not the October plaintiff deadline. A January approval would be a 2027 catalyst but is not equivalent to a binding decision today; underwriting it as certain is premature. The bearish thesis is falsified by material non-CVS unrestricted-access wins, stable refill/dispense trends through the back-to-school period, or guidance maintained without increased commercial spending.

Key Decisions for Investors

• Maintain an underweight/short bias in SPRY only on failed post-gap rallies, preferably after the next earnings call clarifies 2026 revenue and operating-cash impact. Target a further 15-25% downside if consensus revenue is reset; cover if management secures comparable unrestricted access at another top PBM or reaffirms guidance with prescription evidence.
• Do not short CVS on this development. The payer decision is immaterial to CVS earnings; use CVS only as a sector-neutral hedge if expressing a broader long established allergy/anaphylaxis-treatment access basket versus short SPRY.
• Set an alert for SPRY cash runway falling below 12 months on revised guidance or for a material increase in sales-and-marketing spend without corresponding prescription acceleration. Either outcome raises financing/dilution risk over the next 6-12 months and would strengthen the short thesis.
• Avoid treating the class-action filing as a standalone catalyst. Reassess after the next earnings release for updated net-revenue-per-prescription, payer mix, and 2027 access assumptions; absent those data, downside positioning should be sized modestly given biotech short-squeeze and takeover risk.